Biostax Corp (BTAX)

[locicat1]

Now here's one that might have blown by all the PR discussion. Important for all IMUN shareholders to contemplate. This astute poster, to whom I am responding, provided a link to an announcement on the prnewswire of a Research and Markets report publication and availability titled "CAR-T Cell Therapy Market 2016-2026:The Most Hot Topic Discussed Among Oncologists Throughout the Globe." And low and behold who is listed under one of nine company profiles --Immune Therapeutics. Alongside the likes of Celgene, Juno Therapeutics, Kite Pharma (purchased last year by Gilead Sciences for $12 Billion) Novartis AG and Sorrento Therapeutics.

Unfortunately, these marketing compilations have a hefty price tag and so does this -$ 4,500.00. But it sure begs the curiosity-how and why was IMUN selected? Based on what?

Just my own curiosity and sure should be all of yours. IMO, much better fodder for investigation than trying to get credible info from Ms. Gina, Esq.